🇺🇸 FDA
Patent

US 11236152

Neutralizing antibodies to HIV-1 GP41 and their use

granted A61PA61P31/18

Quick answer

US patent 11236152 (Neutralizing antibodies to HIV-1 GP41 and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P31/18